Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
A molecule's path from laboratory bench to pharmacy shelf runs through five connected stages, together forming the drug development pipeline. That path shifts in pace and complexity depending on the modality involved. A peptide program at the preclinical stage, for instance, needs different manufacturing support than a small molecule nearing commercial launch.
Each stage in this drug development process carries its own scientific work and regulatory checkpoints. Progress at each stage also shapes what kind of manufacturing partner a program needs within the pipeline.
Here are the five stages of drug development that make up the pipeline:
The drug development pipeline follows the same broad stages for every modality. What changes is manufacturing complexity and regulatory scrutiny at each stage. Small molecule programs follow established chemical synthesis routes.
Peptide programs use a distinct peptide synthesis approach. Biologic and cell and gene programs need more specialized manufacturing and closer regulatory review. This comparison is further summarized in the table below.
| Stage | Small Molecule | Peptide | Biologic | Cell and Gene |
|---|---|---|---|---|
| Discovery | Chemical synthesis and screening | Sequence design and optimization | Target and cell-line identification | Vector or cell-source selection |
| Preclinical | Standard toxicology models | Stability and degradation testing | Immunogenicity and stability testing | Specialized safety models |
| Clinical Trials | Established trial frameworks | Dose-ranging, growing trial base | Longer trials, immune monitoring | Small, closely monitored groups |
| Regulatory Approval | Well-defined regulatory pathway | Established but still evolving | Biologics-specific review pathway | Often uses specialized designations |
| Manufacturing | Batch or continuous production | Solid or liquid phase synthesis | Cell culture-based bioproduction | Patient-specific or vector-based production |
These differences determine which manufacturing partner a program needs, and how early to bring one in. Programs following the small molecule development process can often use established, high-volume manufacturing routes already common across the industry.
Peptide and biologic programs need specialized process expertise earlier in development. Cell and gene programs add further requirements around handling and facility design. Matching a program to the right expertise at each stage helps avoid delays later in the pipeline.
A drug development pipeline spans 10 to 15 years, from discovery to launch, as per a 2025 analysis by the University of Cincinnati. This is how that time breaks down across the pipeline:
Manufacturing scale-up runs alongside the later part of this window, rather than adding a separate block of time on its own.
A CDMO enters once a molecule needs dedicated process development and scale-up support. Within the 10 to 15 year pipeline, this point usually falls after discovery and early screening are complete. Those earlier stages need deep familiarity with the specific molecule. This is why they stay with internal research teams.
Bringing in CDMO services at this point changes what a company can access:
At Neuland we support this transition through process development and API manufacturing. This work draws on over four decades of industry experience and more than 400 R&D scientists. Our facilities and regulatory approvals let companies move a molecule forward without building that infrastructure themselves.
Choosing the right time to bring in a CDMO depends on a molecule's stage and a company's internal capacity. A CDMO partner guide can help teams weigh that decision further.
Summary Points
Not sure which stage of the pipeline your molecule needs support at?
Neuland's API and peptide manufacturing teams support pharmaceutical and biotech partners from process development through commercial supply. Talk to Neuland's team to map out what your program needs next.
Most drugs fail due to safety concerns or weak efficacy in clinical trials. These problems mostly surface once a molecule is tested in larger patient groups. A smaller share fail later, during regulatory review or manufacturing scale-up.
Companies prioritize molecules in their pipeline based on several factors weighed together. These typically include: Molecules that score poorly on these factors are often deprioritized or shelved altogether. That frees up resources for programs with a clearer path to approval.
The number of drugs depends heavily on company size and therapeutic focus. A large pharmaceutical company might manage dozens of molecules across different stages simultaneously. A smaller biotech, on the other hand, may focus on just one or two programs at a time.
Drug discovery and drug development are related but distinct terms. Discovery covers the early search for a molecule that acts on a disease target. Development covers everything that follows, including clinical trials and manufacturing.
Delays in a drug development pipeline can happen at almost any stage, though certain causes come up repeatedly. Common causes include: Most delays compound rather than stay contained within one stage. A late step often pushes back everything that follows.
